Latvijas Universitates Mediciniskas Pecdiploma Izglitibas Instituts SIA
- Address
- lock Available on a paid plan
Chronic Obstructive Pulmonary Disease (COPD)
The research site concentrates on Respiratory Tract Diseases and is evaluating Chronic Obstructive Pulmonary Disease (COPD) through studies that test novel inhaled treatments to lessen the frequency of disease exacerbations.
- Evaluation of two doses of the inhaled anti‑inflammatory agent CHF6001 added to maintenance triple therapy
- Measurement of moderate and severe COPD exacerbation rates over a 52‑week period
Latvijas Universitates Mediciniskas Pecdiploma Izglitibas Instituts SIA runs patient‑focused trials to improve long‑term outcomes for people with COPD.
Bronchiectasis
In the area of Respiratory Tract Diseases, the institute is investigating Bronchiectasis with a trial designed to determine whether a new oral therapy can significantly reduce pulmonary exacerbations.
- Comparison of BI 1291583 against placebo for annualised adjudicated exacerbation rates
- Focus on superiority in preventing bronchiectasis‑related pulmonary attacks
The centre’s research aims to bring clearer treatment options to patients living with bronchiectasis.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Boehringer Ingelheim Espana S.A.1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Boehringer Ingelheim Espana S.A.2trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 80 other sites in Latvia
Therapeutic Area Benchmark — Latvia
Select a therapeutic area to compare against other sites in Latvia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Latvia
Market Share
Country: Latvia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Latvijas Universitates Mediciniskas Pecdiploma Izglitibas Instituts SIA
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 52-week, randomised, double blind, multicentre, 2-arm parallel group trial assessing the efficacy and safety of CHF6001 (total daily dose 3200 μg) Dry Powder Inhaler (DPI) add-on to maintenance medium or high dose inhaled corticosteroid in combination with long-acting ß2-agonists in subjects with uncontrolled asthma | Chiesi Farmaceutici S.p.A. | Phase II | Not Recruiting | Nov 2023 | Dec 2025 |
IMP list
lock Showing 1 of 5 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Bi 1291583 | 2 | Unknown | 2023-09-05 | 2025-08-21 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.